Nykode Therapeutics ASA
OSE:NYKD
Nykode Therapeutics ASA
Nykode Therapeutics ASA is a clinical-stage biopharmaceutical company which engages in discovering and developing of novel immunotherapies. The company is headquartered in Oslo, Oslo and currently employs 135 full-time employees. The company went IPO on 2020-01-27. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The firm develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeutics’ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The firm also has two universal COVID-19 vaccine candidates in development.
Nykode Therapeutics ASA is a clinical-stage biopharmaceutical company which engages in discovering and developing of novel immunotherapies. The company is headquartered in Oslo, Oslo and currently employs 135 full-time employees. The company went IPO on 2020-01-27. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The firm develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeutics’ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The firm also has two universal COVID-19 vaccine candidates in development.
Cost Reduction: Nykode significantly lowered operating expenses this quarter, more than halving costs year-over-year as a result of streamlining and reduced clinical activities.
Financial Position: The company remains well-capitalized with $64 million in cash and a projected cash runway into 2028, potentially extending into 2029 if a positive tax case outcome is achieved.
Clinical Progress: Key programs (abi-suva, VB10.NEO, and the tolerance platform) advanced, with the pivotal Abili-T Phase II trial protocol submitted to UK authorities and a supply agreement for pembrolizumab secured.
Milestone Timelines: Interim data from the C-03 trial is expected in the first half of 2026, with the first interim Abili-T data anticipated within 24 months of trial start, likely in 2027.
Competitive Advantages: The tolerance platform showed promising multi-parameter immune effects, subcutaneous efficacy, and multi-antigen constructs, all supporting a best-in-class profile.
Partner Interest: Renewed ownership of VB10.NEO has increased partnering discussions, with pharma interest focused on upcoming peer readouts in the individualized neoantigen therapy field.
